Sun Pharma Advanced Research Company has informed that the Company has received an intimation from Shanghvi Finance, a Promoter Group Company, stating that pursuant to an internal restructuring of entities owned / controlled by Dilip Shanghvi, Promoter of SPARC, (DSS Group), they have acquired the controlling share capital of some of the entities forming part of the DSS Group (Holding Companies) from the Promoter of SPARC and his wife on March 30, 2017. Presently, the Holding Companies in turn collectively hold the controlling stake in some of the DSS Group entities, which in turn holds shares in the Company. Consequent to the above acquisition, Shanghvi Finance have gained direct/indirect control on 52.336% of the total share capital of the Company, thereby making Sun Pharma Advanced Research Company its subsidiary in terms of section 2(87)(ii) of the Companies Act, 2013. However, it is pertinent to note that Dilip Shanghvi, will continue to be Promoter of the Company.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Syngene Internation. | 443.50 |
| Indegene | 487.75 |
| CMS Info Systems | 312.95 |
| JITF Infralogistics | 324.65 |
| Sagility | 42.24 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: